Cargando…
A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5
BACKGROUND: Neuronal ceroid lipofuscinosis type 5 (CLN5) is a rare form of neuronal ceroid lipofuscinoses (NCLs) which are a group of inherited neurodegenerative diseases characterized by progressive intellectual and motor deterioration, visual failure, seizures, behavioral changes and premature dea...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216669/ https://www.ncbi.nlm.nih.gov/pubmed/32393339 http://dx.doi.org/10.1186/s12881-020-01039-5 |
_version_ | 1783532459843911680 |
---|---|
author | Li, Wei Fan, Xin Zhang, Yue Huang, Limei Jiang, Tingting Qin, Zailong Su, Jiasun Luo, Jingrong Yi, Shang Zhang, Shujie Shen, Yiping |
author_facet | Li, Wei Fan, Xin Zhang, Yue Huang, Limei Jiang, Tingting Qin, Zailong Su, Jiasun Luo, Jingrong Yi, Shang Zhang, Shujie Shen, Yiping |
author_sort | Li, Wei |
collection | PubMed |
description | BACKGROUND: Neuronal ceroid lipofuscinosis type 5 (CLN5) is a rare form of neuronal ceroid lipofuscinoses (NCLs) which are a group of inherited neurodegenerative diseases characterized by progressive intellectual and motor deterioration, visual failure, seizures, behavioral changes and premature death. CLN5 was initially named Finnish variant late infantile NCL, it is now known to be present in other ethnic populations and with variable age of onset. Few CLN5 patients had been reported in Chinese population. CASE PRESENTATION: In this paper, we report the symptoms of a Chinese patient who suffer from developmental regression and grand mal epilepsy for several years. The DNA was extracted from peripheral blood of proband and both parents, and then whole exome sequencing was performed using genomic DNA. Both sequence variants and copy number variants (CNVs) were analyzed and classified according to guidelines. As the result, a novel frameshift mutation c.718_719delAT/p.Met240fs in CLN5 and a de novo large deletion at 13q21.33-q31.1 which unmasked the frameshift mutation were identified in the proband. Despite the large de novo deletion, which can be classified as a pathogenic copy number variant (CNV), the patient’s clinical presentation is mostly consistent with that of CLN5, except for early developmental delay which is believed due to the large deletion. Both variants were detected simultaneously by exome sequencing. CONCLUSIONS: This is the first report of whole gene deletion in combination with a novel pathogenic sequence variant in a CLN5 patient. The two mutations detected with whole exome sequencing simultaneously proved the advantage of the sequencing technology for genetic diagnostics. |
format | Online Article Text |
id | pubmed-7216669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72166692020-05-18 A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5 Li, Wei Fan, Xin Zhang, Yue Huang, Limei Jiang, Tingting Qin, Zailong Su, Jiasun Luo, Jingrong Yi, Shang Zhang, Shujie Shen, Yiping BMC Med Genet Case Report BACKGROUND: Neuronal ceroid lipofuscinosis type 5 (CLN5) is a rare form of neuronal ceroid lipofuscinoses (NCLs) which are a group of inherited neurodegenerative diseases characterized by progressive intellectual and motor deterioration, visual failure, seizures, behavioral changes and premature death. CLN5 was initially named Finnish variant late infantile NCL, it is now known to be present in other ethnic populations and with variable age of onset. Few CLN5 patients had been reported in Chinese population. CASE PRESENTATION: In this paper, we report the symptoms of a Chinese patient who suffer from developmental regression and grand mal epilepsy for several years. The DNA was extracted from peripheral blood of proband and both parents, and then whole exome sequencing was performed using genomic DNA. Both sequence variants and copy number variants (CNVs) were analyzed and classified according to guidelines. As the result, a novel frameshift mutation c.718_719delAT/p.Met240fs in CLN5 and a de novo large deletion at 13q21.33-q31.1 which unmasked the frameshift mutation were identified in the proband. Despite the large de novo deletion, which can be classified as a pathogenic copy number variant (CNV), the patient’s clinical presentation is mostly consistent with that of CLN5, except for early developmental delay which is believed due to the large deletion. Both variants were detected simultaneously by exome sequencing. CONCLUSIONS: This is the first report of whole gene deletion in combination with a novel pathogenic sequence variant in a CLN5 patient. The two mutations detected with whole exome sequencing simultaneously proved the advantage of the sequencing technology for genetic diagnostics. BioMed Central 2020-05-11 /pmc/articles/PMC7216669/ /pubmed/32393339 http://dx.doi.org/10.1186/s12881-020-01039-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Li, Wei Fan, Xin Zhang, Yue Huang, Limei Jiang, Tingting Qin, Zailong Su, Jiasun Luo, Jingrong Yi, Shang Zhang, Shujie Shen, Yiping A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5 |
title | A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5 |
title_full | A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5 |
title_fullStr | A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5 |
title_full_unstemmed | A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5 |
title_short | A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5 |
title_sort | novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a chinese patient with neuronal ceroid lipofuscinosis type 5 |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216669/ https://www.ncbi.nlm.nih.gov/pubmed/32393339 http://dx.doi.org/10.1186/s12881-020-01039-5 |
work_keys_str_mv | AT liwei anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT fanxin anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT zhangyue anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT huanglimei anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT jiangtingting anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT qinzailong anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT sujiasun anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT luojingrong anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT yishang anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT zhangshujie anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT shenyiping anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT liwei novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT fanxin novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT zhangyue novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT huanglimei novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT jiangtingting novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT qinzailong novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT sujiasun novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT luojingrong novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT yishang novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT zhangshujie novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 AT shenyiping novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5 |